Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.74 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.74 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | ACE | P12821 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7312784 | 0.97 | AGTR1 (0.72) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL8847852 | 0.89 | AGTR1 (0.60) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL7299392 | 0.89 | AGTR1 (0.59) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL9562913 | 0.88 | ALDH1A1 (0.56) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL8848002 | 0.86 | AGTR2 (0.58) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL7312790 | 0.86 | AGTR1 (0.57) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29414101 | 0.85 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29356790 | 0.85 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL2122886 | 0.85 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL4464 | 0.85 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0502314-B1 | Benzimidazol derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-05-20 | — | — | EP | claimed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2003077912-A1 | METHOD OF TREATMENT AND/OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-09-25 | — | — | WO | disclosed |
| EP-0502314-B1 | Benzimidazol derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-05-20 | — | — | EP | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | PPARG 156/4885AGTR1 3252/4885AGTR2 2610/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | PPARG 622/4885AGTR1 8/4885AGTR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.